Researchers have found a novel, pathogenic entity that is a fundamental link between chronic inflammation and tissue destruction in lungs of patients with COPD. These exosomes from activated ...

) has been revised to $137.06 / share. This is an increase of 2,288.89% from the prior estimate of $5.74 dated November 14, 2025. The price target is an average of many targets provided by analysts.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

$PMN insiders have traded $PMN stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales. Here’s a ...

The latest price target for ProMIS Neurosciences (NASDAQ:PMN) was reported by HC Wainwright & Co. on December 1, 2025. The analyst firm set a price target for $18.00 expecting PMN to rise to within 12 ...

Shareholders appeared unconcerned with Phoenix Mecano AG's (VTX:PMN) lackluster earnings report last week. Our analysis suggests that while the profits are soft, the foundations of the business are ...

Biogen Inc. has announced the initiation of the global Phase 3 PROMINENT study to evaluate the efficacy and safety of its investigational anti-CD38 monoclonal antibody, felzartamab, compared to ...